• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Supernus Pharmaceuticals (SUPN)

Common Shares
Sell: $49.20|Buy: $79.96|Change: 0.17 (-0.34%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Address

9715 Key West Avenue
Rockville
MD
USA
20850

Telephone

+1 301 8382522

Website

https://www.supernus.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Supernus Pharmaceuticals Inc Annual Report for 20262027-03-02T00:00:00
Supernus Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20262027-02-24T16:30:00
Supernus Pharmaceuticals Inc Fourth Quarter Earnings Results for 20262027-02-24T00:00:00
Supernus Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-11-04T16:30:00
Supernus Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Supernus Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-08-05T16:30:00
Supernus Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-08-05T00:00:00
Supernus Pharmaceuticals Inc Annual General Meeting for 20262026-06-16T10:00:00
Supernus Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-06T16:30:00
Supernus Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-06T00:00:00

Previous key dates

NameKey Date
Barclays 28th Annual Global Healthcare Conference2026-03-11T14:00:00
Jeeries Biotech on the Beach Summit2026-03-10T00:00:00
TD Cowen 46(th) Annual Health Care Conference2026-03-02T14:30:00
Supernus Pharmaceuticals Inc Annual Report for 20252026-03-02T00:00:00
Supernus Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-02-24T16:30:00
Supernus Pharmaceuticals Inc Fourth Quarter Earnings Result for 20252026-02-24T00:00:00
Bank of America Securities 2025 CNS Therapeutics Virtual Conference2025-12-08T15:20:00
Piper Sandler 37th Annual Healthcare Conference2025-12-02T16:00:00
2025 Jefferies Global Healthcare Conference in London2025-11-17T09:30:00
Supernus Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-04T16:30:00
Supernus Pharmaceuticals Inc Third Quarter Earnings Results for 20252025-11-04T00:00:00
TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit2025-09-18T10:40:00
Wells Fargo Healthcare Conference2025-09-04T08:45:00
Cantor Global Healthcare Conference2025-09-03T08:00:00
Supernus Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-08-05T16:30:00
Supernus Pharmaceuticals Inc Second Quarter Earnings Result for 20252025-08-05T00:00:00
Supernus Pharmaceuticals Inc Annual General Meeting for 20252025-06-16T10:00:00
2025 Jefferies Global Healthcare Conference2025-06-04T14:00:00
Supernus Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-06T16:30:00
Supernus Pharmaceuticals Inc First Quarter Earnings Results for 20252025-05-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.